Naptumomab Estafenatox

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Naptumomab Estafenatox
Accession Number
DB12807
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
ABR-217620
Categories
UNII
93T929W6LC
CAS number
676258-98-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Naptumomab Estafenatox.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Naptumomab Estafenatox.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Naptumomab Estafenatox.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Naptumomab Estafenatox.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Naptumomab Estafenatox.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Naptumomab Estafenatox.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Naptumomab Estafenatox.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Naptumomab Estafenatox.
AmatuximabThe risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Naptumomab Estafenatox.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911384

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Malignant Neoplasm of Pancreas / Renal Cell Adenocarcinoma1
2, 3CompletedTreatmentRenal Cell Adenocarcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 18:23 / Updated on November 02, 2018 07:30